This video explains how the extracellular matrix is the common denominator in all chronic diseases and showcases how the Protein Fingerprint Technology and be used as a sophisticated biomarker tool for tailoring treatment solutions, predicting and monitoring disease progression and treatment response.

This presentation was presented by Morten A. Karsdal, MSc, PhD, mMBA, Professor at the ECM Symposium 2021 organized by Nordic Bioscience.

Morten Asser Karsdal is a Danish molecular biologist and CEO of Nordic Bioscience. Dr. Karsdal has written or cowritten more than 500 peerreviewed articles, achieving more than 25.000 citations and an Hindex of 82, and has given talks at scientific conferences around the world.

Karsdal is recognized for his expertise in biomarker development, including biomarkers that reflect connections between the extracellular matrix and disease biology. He has done extensive research in the field of rheumatology (rheumatoid arthritis and osteoarthritis), diabetes, and fibrosis.

Karsdal spearheaded the development of FDAapproved molecular diagnostics and more than 100 commercialized ELISA assays. He is an Honorary Professor in inflammation research at the University of Southern Denmark and continues to supervise postgraduate students. He wrote his first book: Biochemistry of Collagens, Laminins, and Elastin in 2016, which provides a comprehensive introduction to collagen and structural proteins. He has several US patents.

For more information, please visit our website: https://www.nordicbioscience.com

Or contact us: https://www.nordicbioscience.com/contact

***

Nordic Bioscience is the leading expert in extracellular matrix (ECM) research with 30+ years of experience in biomarker development, preclinical and clinical research. With more than 575 peerreviewed publications, our sciencedriven approach has been the evolving force behind our decades of success.

Through our Protein Fingerprint technology, we identify fragments of the ECM that are released from affected tissues and develop bloodbased biomarker assays to quantify disease activity with the aim of precision medicine.

By quantifying tissue remodeling, our biomarkers provide true prognostic and predictive value, as we can select the patients who are most likely to respond to a given treatment and thereby function as surrogate biomarkers for clinical trials. Our biomarker assays not only enable faster drug development but also improve disease outcomes for chronically ill patients by predicting treatment response.

Nordic Bioscience is headquartered in Herlev, Denmark, with a highquality standard laboratory, running clinical trials under Good Clinical Laboratory Practice (GCLP) with accreditation by the College of American Pathologists (CAP) and ISO9001 certificate. Everything in our laboratory supports compliance to FDA 21 CFR Part 11. We employ more than 180 people who are dedicated to improving patient management for a broad range of therapeutic areas including Hepatology, Rheumatology, Dermatology, Oncology, Gastroenterology, Respiratory, Neurodegenerative and Cardiovascular diseases.

Follow us on our other social media channels to stay informed on the latest news of cuttingedge biomarker research!
LinkedIn:   / nordicbioscience  
Twitter:   / nordic_bio  

#nordicbioscience #lifescience #chronicdiseases #chronic #fibrosis #biomarkers #proteinfingerprint #webinar #extracellularmatrix #ecm